Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
In the last 90 days, Passage BIO, Inc. insiders filed 1 open-market purchase and 0 sales; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Passage BIO, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $206.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$206.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Passage BIO, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Nichols Weston | 10% Owner | 673,759Indirect | Jun 29, 2026 | 1 |
| Lynx1 Capital Management LP | 10% Owner | 673,759Indirect | Jun 29, 2026 | 1 |
| Gowen Maxine | Director | – | May 21, 2026 | 1 |
| Kassberg Thomas Richard | Director | – | May 21, 2026 | 1 |
| Countouriotis Athena | Director | – | May 21, 2026 | 1 |
| Kapadia Sandip | Director | 0 | May 21, 2026 | 1 |
| Porter Derrell | Director | – | May 21, 2026 | 1 |
| Sondhi Dolan | Director | – | May 21, 2026 | 1 |
| Chou William | PRESIDENT AND CEO | 6,524 | Mar 18, 2026 | 3 |
| Borthwick Kathleen | CFO | 5,402 | Mar 18, 2026 | 3 |
| OrbiMed Advisors LLC | 10% Owner | 6,066,343Indirect | Jun 26, 2025 | 0 |
| OrbiMed Capital GP VII LLC | 10% Owner | 6,066,343Indirect | Jun 26, 2025 | 0 |
| Islam Saqib | Director | – | May 30, 2025 | 0 |
| Cale Edgar B. | GC & CORPORATE SECRETARY | 45,995 | Mar 18, 2025 | 0 |
| Forman Mark S | CHIEF MEDICAL OFFICER | 48,631 | Mar 19, 2024 | 0 |
| King Simona | Chief Financial Officer | 23,994 | Aug 1, 2023 | 0 |
| Fotopoulos Alexandros | Chief Technical Officer | 28,693 | Jun 20, 2023 | 0 |
| Kamarck Michael E. | Director | – | May 26, 2023 | 0 |
| Woiwode Thomas | Director, 10% Owner | – | May 26, 2023 | 0 |
| Toernsen Monika Maria | Chief Commercial Officer | 3,319 | Nov 18, 2022 | 0 |
| Goldsmith Bruce A | CEO and President | 15,983 | Jun 1, 2022 | 0 |
| Salinas Eliseo Oreste | Chief Res. & Develop Officer | – | Feb 14, 2022 | 0 |
| Quigley Jill M. | Chief Operating Officer | 368,754 | Dec 10, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 (view filing)4:30 PM ET | Jun 25 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +50.1K | $4.12 | +$206.1K | +8.0%673.8K after | |
| Jan 12, 2026 (view filing) | Jan 8 | 4 days | Borthwick KathleenCFO | SSale | −2.06K | $18.44 | −$38.0K | −27.6%5.40K after | |
| Jan 12, 2026 (view filing) | Jan 8 | 4 days | Chou WilliamPRESIDENT AND CEO | SSale | −4.08K | $18.44 | −$75.2K | −38.5%6.52K after | |
| Sep 15, 2025 (view filing)8:05 PM ET | Sep 11 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share (Common Stock) | +325 | $6.96 | +$2.26K | +0.1%592.0K after | |
| Sep 15, 2025 (view filing)8:05 PM ET | Sep 12-15 | 3 days | Nichols Weston and 1 other10% Owner | PPurchase | +31.7K | $6.99 | +$221.5K | +5.4%623.7K after | 2 lots |
| Jul 24, 2025 (view filing)6:12 PM ET | Jul 22 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +13.1K | $5.44 | +$71.3K | +2.8%476.0K after | |
| Jul 24, 2025 (view filing)6:12 PM ET | Jul 23-24 | 1 day | Nichols Weston and 1 other10% Owner | PPurchase | +115.7K | $5.72 | +$662.5K | +24.3%591.7K after | 2 lots |
| Jun 26, 2025 (view filing)5:10 PM ET | Jun 24-26 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −583.7K | $0.3379 | −$197.2K | −8.8%6.07M after | 3 lots |
| Apr 24, 2025 (view filing)5:38 PM ET | Apr 22-24 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −235.6K | $0.3342 | −$78.7K | −3.4%6.65M after | 3 lots |
| Apr 17, 2025 (view filing)6:10 PM ET | Apr 15-17 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −149.1K | $0.3335 | −$49.7K | −2.1%6.89M after | 3 lots |
| Feb 12, 2025 (view filing) | Feb 11 | 1 day | Borthwick KathleenCFO | SSale | −3.18K | $0.53 | −$1.69K | −7.2%41.3K after | |
| Jan 14, 2025 (view filing)5:17 PM ET | Jan 10-14 | 4 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −223.2K | $0.6371 | −$142.2K | −3.1%7.03M after | 3 lots |
| Jan 8, 2025 (view filing)6:09 PM ET | Jan 6-8 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −147.0K | $0.7026 | −$103.3K | −2.0%7.26M after | 3 lots |
| Dec 31, 2024 (view filing)4:05 PM ET | Dec 27 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share | +373.6K | $0.6451 | +$241.0K | +4.2%9.26M after | |
| Dec 26, 2024 (view filing)4:34 PM ET | Dec 20 | 6 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −230.3K | $0.60 | −$138.2K | −3.0%7.40M after | |
| Dec 11, 2024 (view filing)5:32 PM ET | Dec 9-11 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −62.3K | $0.8348 | −$52.0K | −0.8%7.64M after | 3 lots |
| Dec 6, 2024 (view filing)7:07 PM ET | Dec 4-6 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −97.1K | $0.7965 | −$77.3K | −1.2%7.70M after | 2 lots |
| Nov 27, 2024 (view filing)6:11 PM ET | Nov 25 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.0001 par value per share ("Common Stock") | +260.0K | $0.5641 | +$146.7K | +3.1%8.69M after | |
| Nov 27, 2024 (view filing)6:11 PM ET | Nov 26-27 | 1 day | Nichols Weston and 1 other10% Owner | PPurchase | +196.4K | $0.7021 | +$137.9K | +2.3%8.88M after | 2 lots |
| Sep 23, 2024 (view filing)4:51 PM ET | Sep 19 | 4 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −39.3K | $0.71 | −$27.9K | −0.5%7.79M after | |
| Sep 18, 2024 (view filing)6:38 PM ET | Sep 16-18 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −200.1K | $0.7332 | −$146.7K | −2.5%7.83M after | 3 lots |
| Feb 13, 2024 (view filing) | Feb 13 | Same day | Borthwick KathleenSVP, INTERIM CFO | SSale | −1.47K | $0.97 | −$1.43K | −4.9%28.5K after | |
| Feb 13, 2024 (view filing) | Feb 13 | Same day | Forman Mark SCHIEF MEDICAL OFFICER | SSale | −1.64K | $0.97 | −$1.59K | −3.3%48.6K after | |
| Jan 3, 2024 (view filing) | Jan 2 | 1 day | Forman Mark SChief Medical Officer | SSale | −15.8K | $0.91 | −$14.4K | −25.9%45.3K after | |
| Jan 3, 2024 (view filing) | Jan 2 | 1 day | Borthwick KathleenSVP, Interim CFO | SSale | −10.7K | $0.91 | −$9.71K | −29.2%25.9K after | |
| Jan 3, 2024 (view filing) | Jan 2 | 1 day | Cale Edgar B.GC & Corporate Secretary | SSale | −15.8K | $0.91 | −$14.4K | −25.6%46.0K after | |
| Aug 1, 2023 (view filing) | Jul 28 | 4 days | King SimonaChief Financial Officer | SSale | −11.5K | $0.88 | −$10.1K | −32.3%24.0K after | |
| Jun 29, 2023 (view filing)4:42 PM ET | Jun 27-28 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +1.19M | $0.84 | +$1.00M | +17.4%8.03M after | 2 lots |
| Jun 20, 2023 (view filing) | Jun 16 | 4 days | Fotopoulos AlexandrosChief Technical Officer | SSale | −4.05K | $0.93 | −$3.77K | −12.4%28.7K after | |
| Apr 20, 2023 (view filing) | Apr 18 | 2 days | King SimonaChief Financial Officer | SSale | −2.05K | $1.05 | −$2.16K | −50.0%2.05K after | |
| Dec 2, 2022 (view filing) | Dec 1 | 1 day | Kapadia SandipDirector | SSale | −5.00K | $1.19 | −$5.95K | −100.0%0 after | |
| Nov 25, 2022 (view filing) | Nov 22 | 3 days | Fotopoulos AlexandrosChief Technical Officer | SSale | −3.72K | $1.33 | −$4.95K | −15.5%20.2K after | |
| Nov 18, 2022 (view filing) | Sep 19 | 60 daysLate | Toernsen Monika MariaChief Commercial Officer | SSale | −1.68K | $1.51 | −$2.54K | −33.6%3.32K after | |
| May 5, 2022 (view filing)5:23 PM ET | May 3-4 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +525.0K | $1.94 | +$1.02M | +8.3%6.84M after | 2 lots |
| May 5, 2022 (view filing)5:11 PM ET | Jan 20 | 105 days | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +50.8K | $5.00 | +$254.0K | +0.8%6.32M after | Amended |
| Mar 23, 2022 (view filing) | Mar 21 | 2 days | Goldsmith Bruce ACEO and President | PPurchase | +10.0K | $3.15 | +$31.5K | +167.1%16.0K after | |
| Jan 20, 2022 (view filing)6:03 PM ET | Jan 14-19 | 6 daysLate | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +168.3K | $5.38 | +$905.2K | +2.8%6.27M after | 3 lots |
| Jan 13, 2022 (view filing)7:37 PM ET | Jan 11-13 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +150.0K | $5.61 | +$841.1K | +2.5%6.10M after | 3 lots |